Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
This study has been completed.
Sponsor:
Novartis
Collaborator:
Società Italiana di Urologia (SIU)
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00219219
First received: September 7, 2005
Last updated: November 20, 2009
Last verified: November 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Estimated Study Completion Date: | October 2006 |
| Estimated Primary Completion Date: | No date given |